Open Access

A molecular switch in immunodominant HIV-1-specific CD8 T-cell epitopes shapes differential HLA-restricted escape

  • Henrik N Kløverpris1, 5, 6Email author,
  • David K Cole2Email author,
  • Anna Fuller2,
  • Jonathan Carlson3,
  • Konrad Beck4,
  • Andrea J Schauenburg4,
  • Pierre J Rizkallah4,
  • Søren Buus5,
  • Andrew K Sewell2 and
  • Philip Goulder6
Contributed equally
Retrovirology201512:20

https://doi.org/10.1186/s12977-015-0149-5

Received: 26 November 2014

Accepted: 29 January 2015

Published: 20 February 2015

Abstract

Background

Presentation of identical HIV-1 peptides by closely related Human Leukocyte Antigen class I (HLAI) molecules can select distinct patterns of escape mutation that have a significant impact on viral fitness and disease progression. The molecular mechanisms by which HLAI micropolymorphisms can induce differential HIV-1 escape patterns within identical peptide epitopes remain unknown.

Results

Here, we undertook genetic and structural analyses of two immunodominant HIV-1 peptides, Gag180–188 (TPQDLNTML, TL9-p24) and Nef71–79 (RPQVPLRPM, RM9-Nef) that are among the most highly targeted epitopes in the global HIV-1 epidemic. We show that single polymorphisms between different alleles of the HLA-B7 superfamily can induce a conformational switch in peptide conformation that is associated with differential HLAI-specific escape mutation and immune control. A dominant R71K mutation in the Nef71-79 occurred in those with HLA-B*07:02 but not B*42:01/02 or B*81:01. No structural difference in the HLA-epitope complexes was detected to explain this observation.

Conclusions

These data suggest that identical peptides presented through very similar HLAI landscapes are recognized as distinct epitopes and provide a novel structural mechanism for previously observed differential HIV-1 escape and disease progression.

Keywords

HIV-1 CD8+ T-Cells Viral escape pHLA structure

Background

The human leukocyte antigen (HLA) locus on chromosome 6 is the most polymorphic region of the human genome. The extreme diversity of HLA class I (HLAI) loci allows optimal binding of peptides derived from the vast array of environmental pathogens [1]. The HLAI residues that are polymorphic are mainly those forming the peptide-binding groove, which contains six binding pockets (A to F) that define the size and chemical characteristics of the specific peptide repertoire that can be accommodated by each HLAI molecule. Interaction between peptide and HLAI is usually governed by the compatibility of residues at the N- and C-terminus of the peptide (peptide anchor residues) within the highly polymorphic binding pockets. Cognate T-cell receptors (TCRs) expressed on CD8+ T-cells detect pathogen-derived peptides presented by HLAI molecules on the surface of infected cells [2].

Minor differences between the HLAI molecules expressed (‘HLAI micropolymorphisms’), even of a single amino acid, can have a profound impact on both T-cell immunity and disease outcome during a range of infections, including HIV-1 [3-8]. This disparity has been partly explained by the selection of escape mutations that have different consequences for viral fitness [8-10]. For example, the dominant HIV-1-specific epitope restricted by two closely-related HLAI molecules within the B7 superfamily, HLA-B*42:01 and HLA-B*81:01, is the same peptide, Gag180–188 TPQDLNTML (TL9-p24) [11,12]. The escape mutation selected in each case differs, with variation most commonly arising at Gag-182 (position-3 in the epitope) in HLA-B*42:01-positive subjects, and at Gag-186 (position-7) in HLA-B*81:01-positive subjects. In vitro studies indicate that the escape mutants selected at Gag-186 have a dramatic negative impact on viral replication capacity, in contrast to the minimal effect of mutation at Gag-182 [13]. HLA-B*81:01, together with HLA-B*57 and HLA-B*58:01, is one of the group of HLAI molecules most strongly associated with immune control of HIV-1 [5,14,15] and the viral replicative capacity in HLA-B*81:01+ subjects has been reported to be lower than in subjects expressing any other allele [13]. The mutation principally responsible for this protective effect is the above-mentioned HLA-B*81:01-driven T186S variant that fails to yield replicating virus stocks in studies of C clade virus [13]. This is in line with the lower viral loads and higher CD4 counts observed in HLA-B*81:01 positive subjects in studies of exclusively C-clade infection [9,14,16]. Notably, in a study of cohorts in Zambia, Rwanda and Kenya involving several clades of virus, including clade A which carries a different consensus residue at Gag-186, stable CD4 counts but not lower viraemia was observed in association with HLA-B*81:01 [15].

In this study we focus on two HIV-1-specific epitopes and their presentation by 4 different members of the HLA-B7 superfamily, HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01. These alleles are highly prevalent in Sub-Saharan Africa, the region worst afflicted by the HIV-1 pandemic, one or more being expressed in 35-40% of people comprising these populations [14]. The identical TL9-p24 and Nef71–79, RPQVPLRPM (RM9-Nef) epitopes are presented by these alleles, and represent two of the dominant HIV-1-specific responses in Southern African study cohorts [14], being recognised by approximately 70% and 40%, respectively, of subjects expressing HLA B7-supertype alleles, and targeted by approximately 25% and 20%, respectively of all subjects in Southern African study cohorts, irrespective of HLAI type [14,17].

In the case of both epitopes, TL9-p24 and RM9-Nef, distinct patterns of escape mutations are induced by different HLAI molecules within the B7 superfamily [17]. We here have undertaken a genetic and structural approach to better understand the molecular mechanisms by which HLAI micropolymorphisms can influence the precise nature of T-cell escape and immune control through identical HIV-1 epitopes. These data demonstrate that even a single HLAI polymorphism can switch the conformation of a peptide in the HLAI binding groove, substantially altering both the peptide residues positioned to contact incoming TCRs, and consequently of the impact of variation at different residues within the same epitope.

Results

HLAI micropolymorphisms result in distinct targeting frequencies and selection pressure through two HIV-1 epitopes

We studied four members of the HLA-B7 superfamily, HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01. These closely-related HLAI molecules restrict both distinct and identical HIV-1 epitopes [4,7,18]. The differences in sequence between HLA-B*07:02, B*42:01, B*42:02 and B*81:01 are small (Figure 1A). Atomic resolution of these HLA-B molecules (crystallographic statistics in Additional file 1: Tables S1 and S2) demonstrate that all of the polymorphic positions are part of the HLAI peptide binding pockets (Figure 1B-E) and therefore potentially affect peptide presentation to CD8+ T cells.
Figure 1

Micropolymorphisms within HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01 molecules. (A) HLAI residue polymorphisms within α1 domain (top) and α2 domain (bottom) aligned to HLA-B*07:02. (B-E) The HLAI peptide binding groove shown as grey cartoon with each position in each HLAI coloured individually and shown as sticks for (B) HLA-B*07:02, (C) HLA-B*42:01, (D) HLA-B*42:02 and (E) HLA-B*81:01, at atomic resolution.

To better understand the mechanisms underlying the observed differential HIV-1 selection pressure imposed on HIV-1 by distinct HLAI molecules within the B7 superfamily, we focused on two epitopes, TL9-p24 and RM9-Nef, that dominate the HIV-1-specific CD8 T-cell response in the Southern African HIV-1 epidemic [14,17]. These two epitopes were presented by all four of these HLAI molecules, other than TL9-p24 which was presented by all except HLA-B*42:02 (Figure 2A). TL9-p24, dominantly targeted through HLA-B*42:01 and HLA-B*81:01 and subdominantly through HLA-B*07:02, had a peptide-HLAI (pHLAI) stability of >0.7 h and Tm = 49-55°C, whereas the lack of TL9-p24 targeting via HLA-B*42:02 was associated with low pHLAI stability (<0.2 h, Tm = 37°C) [7]. RM9-Nef, however, was presented by all 4 different HLAIs, with pHLAI stabilities ranging from 1.7 h to 22.4 h (Tm = 52-66°C) (Figure 2B-D).
Figure 2

TL9-p24 and RM9-Nef immunodominance, pHLAI stability and differential selection pressure for HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01. (A) Unbiased screening of n = 1,009 individuals with OLP-25 (GATPQDLNTMLNTVGGH) containing TL9-p24 and OLP-76 (EVGFPVRPQVPLRPMTFK) containing RM9-Nef of which n = 76 where HLA-B*07:02+, n = 154 where HLA-B*42:01+, n = 22 where HLA-B*42:02+ and n = 96 where HLA-B*81:01+. Individuals expressing HLA-B*39:10 (n = 30) were excluded as they also target TL9-24 and RM9-Nef. (B) TL9-p24 (TPQDLNTML) and RM9-Nef (RPQVPLRPM) pHLAI stability (binding half-life, h) against indicated HLA-B molecules. (C, D) CD thermal denaturation curves recorded at 218 nm are shown for selected pHLAI samples. Dots represent measured values fitted assuming a 2-state trimer-to-monomer transition (solid lines) as described in Methods. Insets show bar graphs of the thermal stability with respect to melting temperature (upper) and van’t Hoff’s enthalpy of unfolding (lower panel) using the same color code as in B. (E, F) Intraepitope HIV-1 polymorphisms for (E) TL9-p24 shown on the X-axis for Q182X as peptide position 3 and T186S as position 7 and (F) for RM9-Nef R71K as for peptide position 1 and L76X as position 6 and expressed as the percentage of total viral sequences for n = 1,327 HIV-1 infected individuals of which n = 189 expressed HLA-B*07:02, n = 436 expressed HLA-B*42:01, n = 56 expressed HLA-B*42:02 and n = 213 expressed HLA-B*81:01. Only Q < 0.05 is shown with ***indicating P < 0.0002 and **P < 0.002 compared to HLAI mismatched individuals.

Sequence analysis of >1,200 HIV-1 C-clade infected individuals confirmed striking differences in HLAI-driven selection pressure within both epitopes (Figure 2E) and (Table 1). Of note, selection for the above-mentioned T186S at position 7 of the TL9-p24 epitope (31%, P = 2×10−24) was only significant in HLA-B*81:01-positive individuals. Distinct patterns of selection were also observed for RM9-Nef, even though this epitope was similarly targeted irrespective of the B7 superfamily HLA-B allele expressed (34%-54%). HLA-B*07:02 expressing individuals exhibited strong selection at P1 in the epitope (R71K: 41%, P = 7×10−5), whereas HLA-B*81:01 expressing individuals showed selection of variants at P6 of the epitope (L76V/T/I, L76X, P = 2×10−43) with no selection mediated by HLA-B*42:01 and HLA-B*42:02 on this RM9-Nef epitope (Figure 2F) (Table 1).
Table 1

HLA-B*07:02, 42:01, 42:02 and 81:01-associated TL9-p24 and RM9-Nef HIV-1 polymorphisms

Epitope

HLA-B

HXB2 location

Escape variant selected a

Sequence b

% HLA match

% HLA mismatch

P

Q c

N

TL9-p24

42:01

182

T

EGATP T DLNTMLNTV

9

1

7.0E-07

2.4E-04

1279

81:01

177

D

DGATPQDLNTMLNTV

7

1

4.4E-05

1.1E-02

1283

81:01

182

E

EGATP E DLNTMLNTV

5

0

2.1E-08

7.6E-06

1282

81:01

182

G

EGATP G DLNTMLNTV

8

1

6.2E-06

1.8E-03

1281

81:01

182

S

EGATP S DLNTMLNTV

21

3

6.2E-12

4.3E-09

1277

81:01

186

S

EGATPQDLN S MLNTV

31

3

1.8E-24

8.5E-21

1285

81:01

191

I

EGATPQDLNSMLNTI

9

2

3.2E-06

9.6E-04

1288

RM9-Nef

07:02

71

K

FPVK PQVPLRPMTYK

41

6

7.4E-05

2.4E-02

1293

42:02

81

F

FPVRPQVPLRPMTFK

34

9

1.4E-04

4.0E-02

1126

81:01

76

V

FPVRPQVP V RPMTYK

34

6

3.3E-16

4.8E-13

1327

81:01

76

T

FPVRPQVP T RPMTYK

17

1

1.9E-15

2.3E-12

1327

81:01

76

I

FPVRPQVP I RPMTYK

7

0

4.0E-06

2.1E-03

1327

aEscape polymorphism shows the amino acid selected in that particular HXB2 location, also indicated by bold face.

bEpitope is italics with the consensus shown for +/- 3 amino acids; bold indicates the site of polymorphism.

cOnly Q-values <0.05 are included.

Thus, HLAI micropolymorphisms among these 4 HLA-B alleles result in distinct patterns of immunodominance at a population level. However, even when the frequency of recognition of epitopes was similar, such as TL9-p24 targeting in HLA-B*42:01-positive or HLA-B*81:01-positive subjects; and RM9-Nef targeting in subjects expressing any of the 4 closely-related B7 superfamily HLAI molecules, selection pressure on HIV-1 was HLAI-specific.

A conformational switch induces altered presentation of TL9-p24 by HLA-B*81:01 compared to HLA-B*07:02 and HLA-B*42:01

We hypothesised that differential HLAI-specific selection pressure operating on the same epitope may result from structural differences in the HLA-peptide complex. To explore this notion, we first solved the atomic structures of HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01 with TL9-p24. In addition, we solved the atomic structures of HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01 with RM9-Nef (see below). All structures were determined to extremely high resolutions, between 1.18 Å and 2.09 Å, with crystallographic Rwork/Rfree ratios within accepted limits as shown in the theoretically expected distribution [19] (Additional file 1: Tables S1 and S2). The electron density around the HLAI binding groove and the peptide was unambiguous in all of the structures.

The total number of contacts, buried surface area and surface complementarities were comparable in TL9-p24 structures in complex with HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01 (Table 2). The overall conformation of the TL9-p24 peptide when presented by HLA-B*07:02 and HLA-B*42:01 was virtually identical, with Pro2 and Leu9 acting as the main peptide anchor residues and Asp4, Leu5, Thr7 and Met8 pointing away from the groove for potential interactions with TCRs (Figure 3A). Although peptide positions 1–4 and 8–9 were in similar orientations in both HLA-B*07:02-TL9, HLA-B*42:01-TL9 and HLA-B*81:01-TL9 structures, residues 5–7 in the HLA-B*81:01-TL9 structure, which differs in the peptide-presentation platform by just 4 and 3 residues compared to HLA-B*07:02 and HLA-B*42:01, respectively, were flipped into the opposite orientation (Figure 3A). This ‘conformational switch’ resulted in Leu5 and Thr7 acting as secondary anchor residues in HLA-B*81:01-TL9, as opposed to being solvent exposed in HLA-B*07:02-TL9 and HLA-B*42:01-TL9 complexes. In the HLA-B*81:01-TL9 complex, Asn6 of the peptide acted as the dominant feature pointing out of the groove. In contrast, the same residue served as a secondary anchor residue in HLA-B*07:02-TL9 and HLA-B*42:01-TL9. Thus, unexpected and striking differences in TL9-p24 conformation transform the epitope from the perspective of an incoming TCR restricted by HLA-B*81:01 compared to HLA-B*07:02 and HLA-B*42:01.
Table 2

HLA-TL9 contact table

 

B0702

B8101

B4201

TL9

VdW

HB/SB

VdW

HB/SB

VdW

HB/SB

Thr1

26

4

27

5

23

4

Pro2

24

0

22

0

21

0

Gln3

28

1

26

1

24

2

Asp4

4

1

6

2

5

1

Gln5

0

0

2

1

0

1

Asn6

15

1

6

0

4

1

Thr7

9

3

5

2

7

0

Met8

23

2

8

0

25

2

Leu9

23

4

15

3

24

4

Total

152

16

117

14

133

15

BSA (Å)

1651.8

 

1726.2

 

1654.2

 

SC (Å)

0.741

 

0.741

 

0.714

 

HB = hydrogen bond, SB = salt bridge, vdW = van der Waals interactions, BSA = buried surface area, SC = surface complementarity.

*A 3.4 Å cut-off was used for HBs and SBs, and a 4 Å cut-off was used for vdW.

Figure 3

TL9-p24 exhibits a unique conformation when presented by HLA-B*81:01. Comparison of the presentation modes of HLA-B*07:02-TL9 (green sticks), HLA-B*81:01-TL9 (orange sticks) and HLA-B*42:01-TL9 (yellow sticks), the HLAI binding groove is shown as grey cartoon. (A) Structural alignment of HLA-B*07:02-TL9, HLA-B*81:01-TL9 and HLA-B*42:01-TL9 peptide conformations showing that HLA-B*07:02 and HLA-B*42:01 present TL9-p24 in identical conformations, whereas in HLA-B*81:01 residues 5–7 in TL9-p24 are presented in a distinct conformation (arrows pointing up indicate that the corresponding residue is solvent exposed and available for TCR contact, arrows pointing down indicate that the corresponding residue is buried in the HLA groove; black arrows designate that the residue is in the same orientation in all three structures, colored arrows indicate different residue conformations according to the colors used in each structure). The positions of the circled residues (Leu5, Asn6 and Thr7) may be important to explain differential escape when presented by different HLAIs. (B) HLA-B*07:02 and HLA-B*42:01 contain Trp at residue 147, compared to Leu in HLA-B*81:01. This difference generates a 1.7 Å shift in the HLAα1 helix. (C, D) This shift alters interactions between the HLAI binding groove and residues 7 and 8 in the peptide. (E) HLA-B*07:02 and HLA-B*42:01 contain Arg at residue 156 compared to Leu156 in HLA-B*81:01. This polymorphism alters interactions with the peptide leading to the observed divergent conformations. (F) TL9-p24 residue Gln3 adopts a slightly different conformation in HLA-B*07:02 and HLA-B*42:01 compared to HLA-B*81:01 which contributes to the different position of Asn6 in the peptide. (G) TL9-p24 residues Leu5 and Thr7 form a stabilising interaction in the HLA-B*81:01-TL9 structure that is not present in HLA-B*07:02-TL9, or HLA-B*42:01-TL9. (H) In HLA-B*07:02-TL9 and HLA-B*42:01-TL9, residue Leu5 is the most solvent exposed residue. However, in HLA-B*81:01-TL9, residue Asn6 assumes this role.

To explain how minor HLAI polymorphisms could account for this distinct peptide conformation, we focused on two polymorphic residues, at position 147 and 156 of the three HLAI molecules presenting TL9-p24. HLA-B*07:02 and HLA-B*42:01 have Trp at position 147, whereas HLA-B*81:01 has Leu147 (Figure 3B). This side chain had a substantial impact on the position of the α2 helix of the HLAI, evident by a movement of 1.7 Å towards the peptide for HLA-B*81:01 (Figure 3B), and altered the interaction between the HLAI and the C-terminus of the TL9-p24 peptide. Trp147, in HLA-B*07:02 and HLA-B*42:01, made three van der Waals (VdW) contacts with Thr7 and Met8 in the peptide, compared to just one VdW contact between Leu147 in HLA-B*81:01 and Met8 (Figure 3C, D), contributing to the respective peptide conformations.

A second important difference occurred at HLAI residue 156 (with Arg, Asp and Leu at this position in HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01 respectively) which contributed to the conformational differences observed at peptide residues Gln3, Asn6 and Thr7 (Figure 3E, showing HLA-B*07:02 and HLA-B*81:01). The altered position of peptide residue Gln3 in HLA-B*81:01, compared to that in HLA-B*07:02 and HLA-B*42:01, forced Asn6 to swing up, out and clear of Gln3 in HLA-B*81:01 (Figure 3F). The smaller side chain of Leu156 in HLA-B*81:01 compared to the longer Arg156 in HLA-B*07:02 and Asp156 in HLA-B*42:01 (Figure 3E), enabled peptide residues Leu5 and Thr7 to form interactions stabilizing Asn6 in the flipped orientation in the HLA-B*81:01 structure (Figure 3G). Overall, therefore, the altered network of contacts between the TL9-p24 peptide and the polymorphic residues in HLA-B*81:01, compared to those of HLA-B*07:02 and HLA-B*42:01, resulted in the upward display of different residues within the solvent exposed, central peptide bulge (Figure 3H).

HLAI micropolymorphisms alter direct interactions with the RM9-Nef peptide, explaining differences in pHLAI stability and overall epitope presentation

We next analyzed the structures of HLA-B*07:02, HLA-B*42:01, HLA-B*42:02 and HLA-B*81:01 in complex with the well characterised RM9-Nef epitope. Pro2 and Met9 acted as primary anchor residues and Arg1, Val4 and Arg7 pointed away from the groove for potential TCR interactions (Figure 4A). The total number of contacts, buried surface area and surface complementarities were comparable in all four structures (Table 3). Although the overall conformation of the RM9-Nef peptide backbone was similar for all 4 HLAI molecules, we observed important differences in the side chain orientations that could potentially impact T-cell recognition and viral escape, as detailed below.
Figure 4

HLAI polymorphisms contribute to differences in the fine presentation mode of RM9-Nef. Comparison of the presentation modes of HLA-B*07:02-RM9 (green sticks), HLA-B*81:01-RM9 (orange sticks), HLA-B*42:01-RM9 (yellow sticks) and HLA-B*42:02-RM9 (pink sticks), the HLAI binding groove is shown as grey cartoon. (A) Structural alignment of HLA-B*07:02-RM9, HLA-B*81:01-RM9, HLA-B*42:01-RM9 and HLA-B*42:02-RM9 peptide conformations showing differences around peptide residues Arg1, Leu6 and Arg7 (black arrows pointing up indicate that the corresponding residue is solvent exposed and available for TCR contact, black arrows pointing down indicate that the corresponding residue is buried in the HLA groove; no arrow indicates a position between solvent exposed and buried). The position of the circled residue (Leu6) may be important to explain differential escape when presented by different HLAIs. (B) RM9-Nef residue Leu6 undergoes a 3 Å shift in position in the HLA-B*81:01 structure compared to HLA-B*42:01 and HLA-B*42:02. (C) HLA-B*81:01 contains a Leu at position 156 compared to Arg in HLA-B*07:02 and Asp in HLA-B*42:01 and HLA-B*42:02. This polymorphism alters the interactions between RM9-Nef residue Leu6 and the different HLAIs contributing towards its conformational heterogeneity. (D) HLA-B*81:01 contains a Leu at position 147 compared to Trp in HLA-B*07:02, HLA-B*42:01 and HLA-B*42:02. This polymorphism reduces the interactions between residues Pro8 and Met9 in the peptide and HLA-B*81:01 compared to the other HLAIs. (E) HLA-B*42:02 contains a His at position 9 compared to Tyr in HLA-B*07:02, HLA-B*81:01 and HLA-B*42:01. This polymorphism reduces the interactions between residue Pro2 in the peptide and HLA-B*42:02 compared to the other HLAIs.

Table 3

HLA-RM9 contact table

 

B0702

B8101

B4201

B4202

TL9

VdW

HB/SB

VdW

HB/SB

VdW

HB/SB

VdW

HB/SB

Arg1

37

5

35

4

30

4

30

4

Pro2

23

0

22

0

26

0

21

1

Gln3

27

1

23

2

24

2

26

2

Val4

2

0

2

0

2

0

2

0

Pro5

12

0

10

1

8

0

9

0

Leu6

17

0

6

0

4

0

10

0

Arg7

17

4

4

0

11

0

11

0

Pro8

9

1

9

0

15

1

14

1

Leu9

31

5

30

5

56

10

30

4

Total

175

16

141

12

176

17

153

12

BSA (Å)

1813.8

 

1843.4

 

1720.2

 

1796

 

SC (Å)

0.757

 

0.751

 

0.797

 

0.807

 

HB = hydrogen bond, SB = salt bridge, vdW = van der Waals interactions, BSA = buried surface area, SC = surface complementarity.

*A 3.4 Å cut-off was used for HBs and SBs, and a 4 Å cut-off was used for vdW.

Despite distinct selection pressure at position 1 of RM9-Nef by HLA-B*07:02 (R71K) (Figure 2F) (Table 1), peptide residue Arg1 was in a similar conformation in all 4 HLAIs (Figure 4A). However, the altered conformation of Leu6 in the RM9-Nef-HLA-B*81:01 complex, compared with the other three complexes has similarities with the conformational switch described above in relation to TL9-p24. Leu6 was in an identical position within HLA-B*42:01 and HLA-B*42:02, but moved by 3 Å in HLA-B*81:01 and 1.5 Å in HLA-B*07:02 (Figure 4B). These differences were mediated by polymorphisms at residues 156 and 152 within the α2 helix. The larger side chains of Arg156 and Gln152 in HLA-B*07:02 pushed Leu6 up compared to the smaller side chains of Leu156 and Val152 in HLA-B*81:01 (Figure 4C), changes which may be linked to the L76V/T/I selection that is mediated only by HLA-B*81:01.

The other two major differences in RM9-Nef peptide presentation were located at the junction between HLAI residue 147 and peptide residue Pro8, and between HLAI residue Tyr9 and peptide residue Pro2. The smaller side chain of Leu147 in HLA-B*81:01 formed no contacts with Pro8, whereas Trp147 in the 3 other HLAIs made multiple interactions with Pro8 (Figure 4D). Similarly, in all but HLA-B*42:02, in which the side chain of His9 was too short, Tyr9 could contact Pro2 (Figure 4E). These differences could explain the slightly reduced stability of RM9 bound to HLA-B*81:01 and HLA-B*42:02 (Figure 2B,D).

Discussion

Taken together, these data demonstrate that, from the perspective of the TCR, TL9-p24 ‘looks’ completely different in the context of HLA-B*81:01 than it does in the context of HLA-B*07:02 or HLA-B*42:01. This difference in potential TCR contact residues is consistent with the differential viral escape patterns observed between these closely related HLAI molecules. Indeed, 4 of these differences are only selected by HLA-B*81:01, of which two impact on viral replicative capacity [13].

We were unable to generate enough soluble HLA-B*42:02-TL9 protein to generate a crystal structure, consistent with the low stability and lack of recognition of this pHLAI [7]. HLA-B*42:02 has a unique polymorphism within the B-pocket and contains His at residue 9 as opposed to Tyr9 in HLA-B*07:02, HLA-B*42:01 and HLA-B*81:01 molecules. Tyr9 in HLA-B*07:02, HLA-B*42:01 made direct contacts with the primary N-terminal anchor residue (Pro2) in the TL9-p24 peptide. Thus, His at peptide position 9 could alter this interaction and destabilise the HLA-B*42:02-TL9 complex. This notion is consistent with the lack of detectable responses observed to TL9-p24 in HLA-B*42:02 individuals [7], and is most likely a result of the low HLA-B*42:02-TL9 stability demonstrated here by both peptide-HLAI off-rates and by temperature dependent circular dichroism experiments.

The four closely-related RM9-Nef peptide-HLAI structures show that similar conformations do not preclude HLAI-specific selection pressures, such as for R71K, that is only observed in the context of HLA-B*07:02. Our structural analysis demonstrated that R71 (position 1 in the peptide) pointed up, away from the HLAI groove and could therefore act as a putative TCR contact. Indeed, our previous work has shown that N-terminal peptide residue 1 can serve as an important TCR contact [20] in some systems. However, direct binding by a TCR to this residue would depend on the overall orientation of the TCR as most contacts are usually made with the central bulge of the peptide (normally residues 4–6 in the canonical 9-mer peptide). Thus, sensitivity to changes at peptide N-terminal position 1 would likely be highly dependent on the TCR sequence deployed by T-cells recognising RM9-Nef in the context of divergent HLAIs. Because the selection of self-ligands during thymic education are likely different depending on the HLA type, we speculate that HLA-B*07:02 expressing individuals may select a TCR, sensitive to the R71K mutation, that is not selected in HLA-B*42:01/42:02/81:01 positive individuals. TCR structures obtained from HLA-B*07:02 restricted RM9 specific T-cell clones sensitive to the R71K mutation are needed to investigate this notion further. These findings further highlight that HLA-allele specific HIV sequence changes at a population level are a highly sensitive measure of HLA-allele specific selective immune pressure.

Finally, these data demonstrate that a substantial alteration of the conformation of peptide residue P6 in the HLA-B*81:01-RM9 complex is, as with the TL9-p24 Gag-HLA-B*81:01 structure, associated with the differential selection of escape mutations observed in vivo. These observations in relation to both the TL9-p24 and RM9-Nef epitopes support the notion that different restriction elements presenting the same viral epitope in a structurally distinct conformation have an impact on the patterns of viral escape and, thereby, potentially also on immune control.

Conclusions

These data suggest that identical peptides presented through subtly different HLAI alleles can be recognized as distinct epitopes and provide a novel structural mechanism for previously observed differential HLA allele specific patterns of HIV-1 escape and disease progression.

Methods

Study subjects and HIV-1 sequence analysis

We studied 1,327 adults with chronic antiretroviral therapy (ART)-naïve C-clade HIV-1 infection recruited from Durban, South Africa [8,9] and from the Thames Valley Cohort, United Kingdom [21]. Informed consent was obtained from all participating individuals, and institutional review boards at the University of KwaZulu-Natal, Massachusetts General Hospital, and the University of Oxford approved the study. HIV-1 sequences from Gag and Nef proteins were generated [8] and analyzed [9] as previously described.

IFNγ ELISPOT

The HIV-1 specific CD8+ T-cell responses were determined in gamma interferon (IFNγ) enzyme-linked immunospot (ELISPOT) assays. Frequencies of individuals targeting TL9-p24 contained within overlapping peptide (OLP)-25 (GATPQDLNTMLNTVGGH) and individuals targeting RM9-Nef contained within OLP-76 (EVGFPVRPQVPLRPMTFK) were determined by screening a total of 1,009 individuals as previously described [8,14,22], of which n = 76 where HLA-B*07:02+, n = 154 where HLA-B*42:01+, n = 22 where HLA-B*42:02+ and n = 96 where HLA-B*81:01+. Individuals expressing HLA-B*39:10 (n = 30) were excluded as they also target TL9-p24 and RM9-Nef.

pHLAI stability assays

The measurement of pHLAI stability was determined with a dissociation assay based on radiolabeled β2m and biotinylated HLAI, as recently described [23]. Briefly, biotinylated HLAI heavy chain, 125I-labeled β2m, and peptide were allowed to fold into pHLAI complexes in streptavidin-coated scintillation microplates (Flashplate PLUS, Perkin Elmer, Boston, MA) for 24 h at 18°C. Excess of unlabeled β2m was added and dissociation was initiated by placing the microplate in a scintillation reader (TopCount NXT, Perkin Elmer, Boston, MA) operating at 37°C. The scintillation signal was monitored by continuous reading of the microplate for 24 h. Half-lives were calculated from dissociation curves using the exponential decay equation in Prism v.5.0a (GraphPad, San Diego, CA). Assays were performed in duplicate; the mean value of two experiments is reported.

Additionally, the thermal stability of HLA-B complexes was assessed by circular dichroism (CD) spectroscopy monitoring the change in ellipticities at 218 nm. Data were collected on an Aviv Model 215 spectropolarimeter (Aviv Biomedical Inc., Lakewood, NJ) using an 0.1-cm quartz cell. Proteins were dissolved in PBS at concentrations of 3 μM. Melting curves were recorded in 0.5°C intervals from 4°C up to a maximum temperature when protein aggregation was observed. Melting curves were analyzed assuming a two-state trimer-to-monomer transition from the native (N) to unfolded (U) conformation N3 ↔ 3U with an equilibrium constant K = [U]3/[N3] = F/[3c2(1-F)3] where F and c are the degree of folding and protein concentration, respectively. Data were fitted as described [24]. Fitted parameters were the melting temperature Tm, van’t Hoff’s enthalpy ΔHvH, and the slope and intercept of the native baseline. As all protein complexes aggregated to various degrees upon unfolding, the ellipticity of the unfolded state was set as a constant of −1.36 M−1 cm−1 [25].

Construct design

The HLAI heavy chains and β2m chain were generated by PCR mutagenesis (Stratagene) and PCR cloning. All sequences were confirmed by automated DNA sequencing (Lark Technologies). The HLAI heavy chains (residues 1–248) (α1, α2 and α3 domains), and β2m (residues 1 – 100) were also cloned and used to make the pHLAI complexes. The HLAI α chains and β2m sequences were inserted into separate pGMT7 expression plasmids under the control of the T7 promoter [2].

Protein expression, refolding and purification

Competent Rosetta DE3 E.coli cells were used to produce the HLAI heavy chains and β2m in the form of inclusion bodies (IBs) using 0.5 mM IPTG to induce expression and proteins were chemically refolded as described previously [26,27].

Crystallization, diffraction data collection and model refinement

All protein crystals were grown at 18°C by vapour diffusion via the sitting drop technique. 200 nL of each pHLAI (10 mg/ml) in crystallization buffer (10 mM Tris pH 8.1 and 10 mM NaCl) was added to 200 nL of reservoir solution. HLA-B*07:02-TL9 crystals were grown in 22% PEG 4000 and 0.2 M ammonium sulphate, 0.1 M sodium acetate [28]; HLA-B*81:01-TL9 crystals were grown in TOPS4 in 0.1 M HEPES pH 7.0, 20% PEG 4000 and 0.2 M ammonium sulphate [28]; HLA-B*42:01-TL9 crystals were grown in 10% PEG 6000, 10 mM magnesium chloride; HLA-B*07:02-RM9 crystals were grown in TOPS in 0.1 M sodium cacodylate pH 6, 15% PEG 8000 and 15% glycerol [28]; HLA-B*81:01-RM9 crystals were grown in TOPS in 0.1 M Tris pH 8.0, 15% PEG 4000 and 15% glycerol [28]; HLA-B*42:01-RM9 crystals were grown in 10% PEG 6000, 10 mM magnesium chloride; HLA-B*42:02-RM9 crystals were grown in 10% PEG 6000, 10 mM magnesium chloride [28]. All crystals were soaked in 30% ethylene glycol before cryo-cooling. All crystallization screens and optimization experiments were completed using an Art-Robbins Phoenix dispensing robot (Alpha Biotech Ltd, UK). Data were collected at 100 K at the Diamond Light Source, Oxfordshire, UK. All datasets were collected at a wavelength of 0.98 Å using an ADSC Q315 CCD detector. Reflection intensities were estimated with the XIA2 package (Winter G.) and the data were scaled, reduced and analyzed with SCALA and the CCP4 package (Collaborative Computational Project 1994). Structures were solved with molecular replacement using PHASER [29]. Sequences were adjusted with COOT [30] and the models refined with REFMAC5. Graphical representations were prepared with PYMOL (DeLano, 2002). The reflection data and final model coordinates were deposited with the PDB database (HLA-B*07:02-TL9, PDB: 4U1H; HLA-B*81:01-TL9, PDB: 4U1I; HLA-B*42:01-TL9, PDB: 4U1J; HLA-B*07:02-RM9, PDB: 4U1K; HLA-B*81:01-RM9, PDB: 4U1L; HLA-B*42:01-RM9, PDB: 4U1M; HLA-B*42:02-RM9, PDB: 4U1N).

Notes

Abbreviations

HLAI: 

Human leukocyte antigen class I

TCR: 

T cell receptor

Declarations

Acknowledgements

P.G. and A.K.S. are Wellcome Trust Senior Investigators. D.K.C. is a Wellcome Trust Research Career Development Fellow (WT095767). H.N.K holds a grant from the Danish Agency for Science, Technology and Innovation #12-132295 and the Lundbeck Foundation #R151-2013-14624. This work was supported by the UK Biotechnology and Biological Sciences Research Council (Grant BB/ H001085/1) and the National Institutes of Health, grant R01 AI46995. P.J.R. was supported by a RCUK Fellowship. We thank the staff at Diamond Light Source for providing facilities and support.

Authors’ Affiliations

(1)
KwaZulu- Natal Research Institute for Tuberculosis and HIV, K-RITH, Nelson R Mandela School of Medicine, University of KwaZulu-Natal
(2)
Cardiff University School of Medicine, Heath Park
(3)
Microsoft Research, eScience Group
(4)
Cardiff University School of Dentistry
(5)
Department of International Health, Immunology and Microbiology, University of Copenhagen
(6)
Department of Paediatrics, University of Oxford

References

  1. Trowsdale J. HLA genomics in the third millennium. Curr Opin Immunol. 2005;17:498–504.View ArticlePubMedGoogle Scholar
  2. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature. 1996;384:134–41.View ArticlePubMedGoogle Scholar
  3. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med. 2001;344:1668–75.View ArticlePubMedGoogle Scholar
  4. Geldmacher C, Metzler IS, Tovanabutra S, Asher TE, Gostick E, Ambrozak DR, et al. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood. 2009;114:1553–62.View ArticlePubMed CentralPubMedGoogle Scholar
  5. Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity. 2012;37:426–40.View ArticlePubMed CentralPubMedGoogle Scholar
  6. Jin X, Gao X, Ramanathan Jr M, Deschenes GR, Nelson GW, O’Brien SJ, et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8 + −T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol. 2002;76:12603–10.View ArticlePubMed CentralPubMedGoogle Scholar
  7. Kloverpris HN, Harndahl M, Leslie AJ, Carlson JM, Ismail N, van der Stok M, et al. HIV control through a single nucleotide on the HLA-B locus. J Virol. 2012;86:11493–500.View ArticlePubMed CentralPubMedGoogle Scholar
  8. Kloverpris HN, Stryhn A, Harndahl M, van der Stok M, Payne RP, Matthews PC, et al. HLA-B*57 micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control. J Virol. 2012;86:919–29.View ArticlePubMed CentralPubMedGoogle Scholar
  9. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol. 2012;86:5230–43.View ArticlePubMed CentralPubMedGoogle Scholar
  10. Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, et al. Central role of reverting mutations in HLA associations with human immunodeficiency virus set point. J Virol. 2008;82:8548–59.View ArticlePubMed CentralPubMedGoogle Scholar
  11. Goulder PJ, Brander C, Annamalai K, Mngqundaniso N, Govender U, Tang Y, et al. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children. J Virol. 2000;74:5679–90.View ArticlePubMed CentralPubMedGoogle Scholar
  12. Honeyborne I, Rathod A, Buchli R, Ramduth D, Moodley E, Rathnavalu P, et al. Motif inference reveals optimal CTL epitopes presented by HLA class I alleles highly prevalent in southern Africa. J Immunol. 2006;176:4699–705.View ArticlePubMedGoogle Scholar
  13. Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder PJ, et al. Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol. 2012;86:3193–9.View ArticlePubMed CentralPubMedGoogle Scholar
  14. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature. 2004;432:769–75.View ArticlePubMedGoogle Scholar
  15. Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, et al. HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race? J Virol. 2013;87:4043–51.View ArticlePubMed CentralPubMedGoogle Scholar
  16. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung’u T, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol. 2010;84:9879–88.View ArticlePubMed CentralPubMedGoogle Scholar
  17. Leslie A, Price DA, Mkhize P, Bishop K, Rathod A, Day C, et al. Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol. 2006;177:4699–708.View ArticlePubMedGoogle Scholar
  18. Kloverpris HN, Adland E, Koyanagi M, Stryhn A, Harndahl M, Matthews PC, et al. HIV subtype influences HLA-B*07:02-associated HIV disease outcome. AIDS Res Hum Retroviruses. 2014;30:468–75.View ArticlePubMedGoogle Scholar
  19. Tickle IJ, Laskowski RA, Moss DS. Rfree and the rfree ratio. II. Calculation of the expected values and variances of cross-validation statistics in macromolecular least-squares refinement. Acta Crystallogr D Biol Crystallogr. 2000;56:442–50.View ArticlePubMedGoogle Scholar
  20. Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, et al. Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem. 2009;284:27281–9.View ArticlePubMed CentralPubMedGoogle Scholar
  21. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B*2705-restricted CD8+ T cells. J Virol. 2010;84:10543–57.View ArticlePubMed CentralPubMedGoogle Scholar
  22. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46–53.View ArticlePubMedGoogle Scholar
  23. Harndahl M, Rasmussen M, Roder G, Buus S. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods. 2011;374(1-2):5-12.Google Scholar
  24. Greenfield NJ. Analysis of circular dichroism data. Methods Enzymol. 2004;383:282–317.View ArticlePubMedGoogle Scholar
  25. Venyaminov S, Baikalov IA, Shen ZM, Wu CS, Yang JT. Circular dichroic analysis of denatured proteins: inclusion of denatured proteins in the reference set. Anal Biochem. 1993;214:17–24.View ArticlePubMedGoogle Scholar
  26. Cole DK, Dunn SM, Sami M, Boulter JM, Jakobsen BK, Sewell AK. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Mol Immunol. 2008;45:2700–9.View ArticlePubMedGoogle Scholar
  27. Cole DK, Rizkallah PJ, Gao F, Watson NI, Boulter JM, Bell JI, et al. Crystal structure of HLA-A*2402 complexed with a telomerase peptide. Eur J Immunol. 2006;36:170–9.View ArticlePubMedGoogle Scholar
  28. Bulek AM, Madura F, Fuller A, Holland CJ, Schauenburg AJ, Sewell AK, et al. TCR/pMHC optimized protein crystallization screen. J Immunol Methods. 2012;382:203–10.View ArticlePubMed CentralPubMedGoogle Scholar
  29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40:658–74.View ArticlePubMed CentralPubMedGoogle Scholar
  30. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–32.View ArticlePubMedGoogle Scholar

Copyright

© Kløverpris et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement